Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma/COPD;Einsatz von β-blockern bei kardiovaskulären erkrankungen und asthma bronchiale/COPD

Internist

Volumn 45, Issue 2, 2004, Pages 221-227

  Glaab, T ^a   Weiss, T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Asthma; Beta Blocker; Chronic heart failure; Chronic obstructive pulmonary disease; Myocardial infarction

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE;

ARTICLE; ASTHMA; CARDIOSELECTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG TOLERABILITY; DRUG USE; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MORTALITY; RISK BENEFIT ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ASTHMA; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; METABOLIC CLEARANCE RATE; MYOCARDIAL INFARCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1242269390     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-1093-3     Document Type: Article

References (28)

1. Bertrand M, Simoons M, Fox K et al. (2002) Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (Task Force Report). Eur Heart J 23: 1809-1840 http://www.escardio.org
2. Cesario D, Fonarow G (2002) Beta-blocker therapy for heart failure: the standard of care. Rev Cardiovasc Med 3: 14-21
3. Chen J, Radford M, Wang Y, Marciniak T, Krumholz H (2001) Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 37: 1950-1956
4. Deutsche Hochdruckliga (2002) Empfehlungen zur Hochdruckbehandlung.
5. Donohue J, Van Noord J, Bateman E, Langley S, Lee A, Witek T, Kesten S, Towse L (2002) A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122: 47-55
6. Freemantle N, Cleland J, Young P, Mason J, Harrison J (1999) β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318: 1730-1737
7. Global Initiative for Asthma, National Heart, Lung and Blood Institute, World Health Organization (2002) Global initiative for asthma. Global strategy for asthma management and prevention. http://www.ginasthma.com
8. Gottlieb S, McCarter R, Vogel R (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339: 489-497
9. Heller D, Ahem F, Kozak M (2000) Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction. Am Heart J 140: 663-671
10. Hoffmann J, Maisch B (2002) β-Rezeptoren-Blocker bei koronarer Herzkrankheit. In: Hoffmann J, Maisch B (Hrsg) Beta-Blocker bei kardiovaskulären Erkrankungen. Uni-Med, Bremen, S 42-77
11. Hoffmann J, Grimm W, Maisch B (2002) Betablocker in der Therapie der chronischen Herzinsuffizienz. Herz 27: 150-165
12. Hunt S, Baker D, Chin M et al. (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 38: 2101-2113;http://www.acc.org
13. Komajda M, Follath F, Swedberg K et al. (2003) The Euro-Heart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24: 464-474
14. Lama P (2002) Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Opthalmol 134: 749-760
15. Lüllmann H, Mohr K (Hrsg) (1999) Pharmakologie und Toxikologie. Thieme, Stuttgart New York, S 83-87
16. Messerli F, Grossman E, Goldbourt U (1998) Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA 279: 1903-1907
17. Motomura S, Deighton N, Zerkowski H, Doetsch N, Michel H, Brodde O (1990) Chronic beta 1-adrenoceptor antagonist treatment sensitizes beta 2-adrenoceptors, but desensitizes M2-muscarinic receptors in the human right atrium. Br J Pharmacol 101: 363-369
18. Poole-Wilson P, Swedberg K, Cleland J et al. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprotol European Trial (COMET): randomised controlled trial. Lancet 362: 7-13
19. Ryan T, Anderson J, Antman E et al. (1996) ACC/AHA guidelines for management of patients with acute myocardial infarction. Circulation 94: 2341-2350 (update 2002: http://www.acc.org)
20. Salpeter S, Ormiston T, Salpeter E (2002) Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 137: 715-725
21. Salpeter S, Ormiston T, Salpeter E, Poole P, Cates C (2003) Cardioselective beta-blockers for chronic obstructive pulmonary disease (Cochrane Review). Cochrane Library, Issue 1
22. Smith L, McFadden E (1995) Bronchial hyperreactivity revisited. Ann Allerg Asthma Immunol 74: 454-470
23. Van de Werf F, Ardissino D, Betriu A et al. (2003) Management of acute moycardial infarction in patients presenting with ST-segment elevation (Task Force Report). Eur Heart J 24: 28-66; http://www.escardio.org
24. Wehling M (2002) β-Blocker und ihre Bedeutung für die Pharmakotherapie kardiovaskulärer Erkrankungen im Vergleich. Arzneimittelforschung 52: 73-80
25. Wellstein A, Palm D, Belz G (1986) Concentration kinetics of propranolol, bisoprolol and atenolol in humans assessed with chemical detection and a subtype selective adrenoceptor. J Cardiovasc Pharmacol 8 (Suppl): 42-47
26. Wettengel R, Berdel D, Hofmann D et al. (1998) Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie. Med Klin 93: 639-650
27. Worth H, Buhl R, Cegla U et al. (2002) Leitlinie der deutschen Atemwegsliga und der deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 56: 704-738
28. Worth H (2001) Beta-Blocker bei Asthma und COPD - ein therapeutisches Dilemma? Pneumologie 55: 53-56